What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2021-11-15 compared with 2021-08-16 · 53 added, 9 removed, 20 unchanged (76% of the section changed)

1 unchanged sentence

following exhibits are filed as part of this report:

Third Amended and Restated Certificate of Incorporation previously filed with the SEC on July 7, 2021 as Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No.

Amended and Restated Certificate of Incorporation previously filed with the SEC on July 7, 2021 as Exhibit 3.1 to the Company’s

Current Report on Form 8-K (File No.

001-38306), which is incorporated herein by reference.

Amended and Restated Bylaws previously filed with the SEC on July 7, 2021 as Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No.

and Restated Bylaws previously filed with the SEC on July 7, 2021 as Exhibit 3.2 to the Company’s Current Report on Form 8-K

001-38306), which is incorporated herein by reference.

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Executive Officer Pursuant to 18 U.S.C.

of Senior Secured Convertible Promissory Note issued by the Company pursuant to and in accordance with the Securities Purchase Agreement

(incorporated by reference to Exhibit 4.6 filed with Ensysce Biosciences, Inc.’s Current Report on Form 8-K on September 27,

of Common Stock Purchase Warrant to be issued by the Company pursuant to and in accordance with the Securities Purchase Agreement

(incorporated by reference to Exhibit 4.7 filed with Ensysce Biosciences, Inc.’s Current Report on Form 8-K on September 27,

Purchase Agreement, dated September 24, 2021, by and among the Company and the purchasers signatory thereto (incorporated by reference

to Exhibit 10.1 filed with Ensysce Biosciences, Inc.’s Current Report on Form 8-K on September 27, 2021).

Rights Agreement, dated September 24, 2021, by and among the Company and the parties signatory thereto(incorporated by reference

to Exhibit 10.2 filed with Ensysce Biosciences, Inc.’s Current Report on Form 8-K on September 27, 2021).

Guarantee, dated September 24, 2021, by and among the Company and the purchasers signatory thereto(incorporated by reference to Exhibit

10.3 filed with Ensysce Biosciences, Inc.’s Current Report on Form 8-K on September 27, 2021).

Agreement, dated September 24, 2021, by and among the Company, EBI OpCo, Inc., Covistat, Inc.

and the other parties signatory thereto

(incorporated by reference to Exhibit 10.4 filed with Ensysce Biosciences, Inc.’s Current Report on Form 8-K on September 27,

Security Agreement, dated September 24, 2021, by and among the Company, EBI OpCo, Inc., Covistat, Inc.

and the other parties signatory

thereto (incorporated by reference to Exhibit 10.5 filed with Ensysce Biosciences, Inc.’s Current Report on Form 8-K on September

of Indemnification Agreement executed by each of the Ensysce directors and executive officers (incorporated by reference to Exhibit

10.2 filed with Ensysce Biosciences, Inc.’s Current Report on Form 8-K on July 7, 2021).

Certification

of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant

to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification

of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant

to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification

of Principal Executive Officer Pursuant to 18 U.S.C.

Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of

Certification of Principal Financial Officer Pursuant to 18 U.S.C.

Certification

of Principal Financial Officer Pursuant to 18 U.S.C.

Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of

Presentation furnished as of July 21, 2021.

(incorporated by reference to Exhibit 99.1 filed with Ensysce Biosciences, Inc.’s

Current Report on Form 8-K on July 21, 2021).

Release, dated July 21, 2021 (incorporated by reference to Exhibit 99.2 filed with Ensysce Biosciences, Inc.’s Current Report

on Form 8-K on July 21, 2021).

Release, dated November 8, 2021 (incorporated by reference to Exhibit 99.1 filed with Ensysce Biosciences, Inc.’s Current Report

on Form 8-K on November 10, 2021).

Release, dated August 16, 2021 (incorporated by reference to Exhibit 99.1 filed with Ensysce Biosciences, Inc.’s Current Report

on Form 8-K on August 17, 2021).

Release, dated as of July 8, 2021 (incorporated by reference to Exhibit 99.1 filed with Ensysce Biosciences, Inc.’s Current

Report on Form 8-K on July 8, 2021).

Release, dated as of July 1, 2021 (incorporated by reference to Exhibit 99.1 filed with Ensysce Biosciences, Inc.’s Current

Report on Form 8-K on July 1, 2021).

Release, dated as of June 30, 2021 (incorporated by reference to Exhibit 99.1 filed with Ensysce Biosciences, Inc.’s Current

Report on Form 8-K on July 1, 2021).

Release, dated as of June 30, 2021 (incorporated by reference to Exhibit 99.2 filed with Ensysce Biosciences, Inc.’s Current

Report on Form 8-K on July 1, 2021).

Instance Document

4 unchanged sentences

Taxonomy Extension Presentation Linkbase Document

Cover Page Interactive

Data File (embedded within the Inline XBRL document)

Filed herewith.

to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf

by the undersigned, thereunto duly authorized in the City of San Diego, State of California, on this 16th day of August, 2021.

by the undersigned, thereunto duly authorized in the City of San Diego, State of California, on this 15th day of November, 2021.

BIOSCIENCES, INC.

August 16, 2021

November 15, 2021

Lynn Kirkpatrick

1 unchanged sentence

and Chief Executive Officer

August 16, 2021

November 15, 2021

David Humphrey

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information